US-Iran Conflict Nearing End, Gold Set for Fifth Straight Gain
BlockBeats News, April 2nd: Spot Gold rose by 0.8% intraday, briefly breaking through $4800 per ounce, recording a fifth consecutive day of gains. Market analysis believes that the resonance of geopolitical tensions and policy expectations is driving continued inflow of safe-haven funds into the gold price.
On the news front, Trump is planning to announce during the gold trading hours that the military action against Iran "has achieved all objectives," indicating the end of the war and paving the way for the gradual U.S. withdrawal from the conflict.
At the same time, the U.S. may hand over the issue of shipping in the Strait of Hormuz to NATO and European and Gulf countries, indicating that the United States is seeking a "dignified exit" path.
Against the backdrop of Iran's continued restriction of strait navigation and international oil prices breaking through $100 per barrel, the market's concerns about the uncertainty of the Middle East situation and energy shocks are rising. Coupled with the policy games and alliance disagreements under the expectation of war "coming to an end," the strengthening of safe-haven demand further boosts the gold price.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.
Tradr ETFs announced that its two leveraged products linked to SK Hynix ADRs will be liquidated and delisted around November 12, with one being long and the other short. Despite only being listed for a few months, their combined scale has shrunk to about $1.3 million, down more than 60% from their peak. SK Hynix's Seoul stock price has fallen 56% from its high, similar products in the industry are generally under pressure, and South Korea has also further tightened regulations on leveraged products.
WTI Price Forecast: Slides further below $100.50; bullish potential seems intact
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.
Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.
Crypto prices
More
